Sabate JM et al. Naloxegol for the Treatment of Opioid-Induced Constipation in Patients with Cancer Pain: A Pooled Analysis of Real-World Data. Cancers 2025; 17(5): 865: 1-13.
Fachinformation MOVENTIG^®, aktueller Stand.
Anantharamu T et al. Naloxegol: First oral peripherally acting mu opioid receptor antagonists for opioid-induced constipation. J Pharmacol Pharmacother 2015;6(3):188-92.
Andresen V et al. The patient burden of opioid-induced constipation: New insights from a large, multinational survey in five European countries. United European Gastroenterol J. 2018; 6(8):1254-1266.
Andresen V et al. Aktualisierte S2k-Leitlinie chronische Obstipation der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Neurogastroenterologie & Motilität (DGNM) – April 2022 – AWMF-Registriernummer: 021–019. Z Gastroenterol. 2022; 60(10):1528-1572.
Bell TJ. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med. 2009; 10(1):35-42.
Überall MA. DGS-Praxisleitlinie Opioidinduzierte Obstipation 2019, V2.0.
Pergolizzi JV et al. The Use of Peripheral μ-Opioid Receptor Antagonists (PAMORA) in the Management of Opioid-Induced Constipation: An Update on Their Efficacy and Safety. Drug Des Devel Ther. 2020; 14:1009-1025.